Arvinas Q3 net loss widens 54% to $53.9 million; Q3 revenue drops 99% to $500,000

• Arvinas’ third-quarter 2026 net loss widened 54% year over year to $53.9 million.
• Revenue dropped 99% year over year to $500,000, consisting of sales-based royalties under the Rigel license agreement.
• Patient dosing began in the Phase 1/2 trial of ARV-6723, its first immuno-oncology degrader, for advanced solid tumors.
• Cash resources are expected to fund planned operating expenses and capital expenditures into the second half of 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arvinas Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611030700PRIMZONEFULLFEED9868778) on November 03, 2026, and is solely responsible for the information contained therein.